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Kåre Hornbech, MD, Jesper Ravn, MD, and Daniel Andreas Steinbru¨chel, DMSc
Introduction: In this study, we analyze the results of management
of pulmonary metastases in 5 years consecutive operations at our
institution. We aim to define the patients who are most likely to
benefit from surgery by investigating long-term survival and prog-
nostic factors associated with prolonged survival.
Methods: The data on all consecutive patients between 2002 and
2006 were reviewed retrospectively. One hundred seventy-eight
patients underwent 256 surgical resections for suspected pulmonary
metastases from different primary malignancies. Prognostic factors
analyzed included age, sex, surgical approach, surgical resection,
number of metastases, distribution of metastases, disease-free inter-
val, presence of synchronous metastases, recurrence of disease, prior
liver resection (colorectal cancer), and tumor histology (sarcomas).
Results: Complete resection was achieved in 248 cases (96.8%).
The mean follow-up was 61.6 months. Five-year survival with
respect to primary malignancy was colorectal carcinoma (50.3%),
sarcoma (21.7%), malignant melanoma (25.0%), renal cell carci-
noma (51.4%), and miscellaneous malignancies (50.0%). Of the
prognostic factors analyzed by univariate analysis, none was found
to be significant in all the different groups of cancers.
Conclusions: Pulmonary metastasectomy is a safe and effective
treatment that may be associated with prolonged survival in highly
selected patients. Low morbidity and mortality rates in contrast with
the lack of any other effective treatment justify the aggressive
approach of surgery. Thoracoscopic resection is a valid option in
selected patients. In case of recurrence of pulmonary disease and if
the patient fulfils the initial criteria for pulmonary metastasectomy,
repeat surgery should be performed. Solid prognostic factors still
need to be established.
Key Words: Lung, Metastases/metastasectomy, Thoracoscopy/
VATS, Thoracotomy.
(J Thorac Oncol. 2011;6: 1733–1740)
Metastatic spread of malignant disease remains one of themajor obstacles when treating patients with cancer. The
lungs are the most common organ to which cancer metasta-
sizes, and approximately 30% of all patients with cancer will
develop lung metastases at some point.1 Pulmonary metasta-
sectomy has been performed for decades, and numerous
retrospective series have demonstrated long-term survival
superior to conventional oncological treatment. Many prog-
nostic factors have been analyzed and the ones that primarily
emerge are as follows: number of pulmonary metastases,
disease-free interval (DFI), radical surgery, and for colorectal
cancer, level of preoperative carcinoembryonic antigen.
Today, despite the lack of randomized studies, pulmo-
nary metastasectomy is considered an accepted therapeutic
option in selected patients as a treatment of proved value.
With the advancements in anesthetical and surgical tech-
niques, the safety of surgery has improved and the indications
for surgery have been extended more widely. More and more
patients are now being referred to thoracic departments for
pulmonary metastasectomy. In a recent survey by Internullo
et al.,2 among the members of the European Society of
Thoracic Surgeon, lung metastasectomy represented up to
10% of clinical volume, and the need for solid prognostic
factors remains strong and has yet to be established.
In this study, we analyze the results of management of
pulmonary metastases in 5 years consecutive and recent
operations at our institution. We aim to define those patients
who are most likely to benefit from surgical treatment by
investigating outcome, long-term survival, and prognostic
factors associated with prolonged survival.
MATERIALS AND METHODS
Between January 2002 and December 2006, 307 oper-
ations for suspected pulmonary metastases were performed at
our institution. The operative data were entered into the
Patient Analysis & Tracking System, version 1108-UK16.
When these data and patient charts were reviewed retrospec-
tively, one operation was performed because of pain and
another because of continuous air leakage. These two oper-
ations were therefore excluded. Two patient charts account-
ing for two operations could not be located and were thus also
excluded. Of the remaining 303 operations, 47 were solely for
diagnostic purpose and therefore not with curative intent.
Thus, these were excluded. Therefore, a total of 256 pulmo-
nary resections with curative intent were included in this
study.
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The patients eligible for curative surgery were to meet
the following standard criteria1: primary tumor was con-
trolled,2 no extra-thoracic lesions were detected (with the
exception of hepatic lesions in which it was possible to
completely remove both hepatic and pulmonary metastases),3
the metastases were technically resectable, and4 the general
and functional risks were tolerable.
Preoperative diagnostic assessment to exclude extra-
thoracic disease and to assess patient risks included chest
x-ray, chest and abdominal computed tomographic (CT) scan,
and cardiac and pulmonary function tests (spirometry, elec-
trocardiogram and/or pulmonary perfusion scintigram, echo-
cardiogram, and positron emission tomography/CT). In some
patients, bronchomediastinoscopy was performed to exclude
malignant disease in the hilar and/or mediastinal lymph nodes
if suspected by CT. Lymph node dissection was not system-
atic and only performed with the detection of malignancy
suspect lymph nodes during surgery.
The medical charts for all patients were reviewed for
age, gender, primary tumor, date of primary tumor operation,
date of pulmonary resection, surgical approach, type of re-
section, location and number of metastases, DFI, 30-day
mortality and morbidity, and duration of survival. DFI was
defined as the time from the date of primary tumor surgery till
the date of pulmonary metastasectomy. Survival was calcu-
lated from the time of pulmonary metastasectomy to death or
the date of last follow-up. All available survival data were
updated in January 2010 for a minimum follow-up of 36
months. Survival status of the patients was obtained from the
Danish National Registry.
Data on preoperative level of carcinoembryonic antigen
were only available in a few patients and therefore not
analyzed. Moreover, data on neoadjuvant and adjuvant
chemotherapy/radiotherapy were not readily available for
analysis.
In total, 256 thoracic procedures with curative intent
were performed in 178 patients. The surgical approach was
chosen according to the location and number of metastases.
One hundred forty-three thoracotomies and 60 video-assisted
thoracoscopic surgery (VATS) were performed. In 53 pa-
tients, the operation was initiated as VATS but was converted
to thoracotomy because of inability to achieve radical resec-
tion thoracoscopically. The type of pulmonary resection
ranged from predominantly wedge resection to extra-pleural
pneumonectomy in one patient.
Table 1 is a summary of surgical approach and types of
resection.
Statistical Analysis
The data were analyzed using the SPSS for Windows
software (Statistical Package for Social Science, SPSS Inc,
version 15.0). Probability of survival was analyzed according
to the Kaplan-Meier method using the date of pulmonary
resection as the starting point. For patients who underwent
staged bilateral surgery, the date of the first operation was
used as starting point. The significance of differences be-
tween variables was analyzed using the log-rank test. A p
value of 0.05 or less was considered significant.
Factors analyzed included age (/60 years), sex,
surgical approach (VATS versus thoracotomy), surgical re-
section (wedge resection versus all other), number of metas-
tases, distribution of metastases (unilateral versus bilateral),
DFI, presence of synchronous metastases, recurrence of pul-
monary disease, prior liver resection (colorectal cancer only),
and tumor histology (sarcomas only). In Table 2 the results
are summarized.
RESULTS
The 30-day mortality was 1.9% (5/256). One patient
with hepatocellular carcinoma with benign histology from the
resected lung lesion was discharged to another ward and died
4 days after. Of the patients with radical metastasectomy,
three patients died due to the following complications: fatal
stroke, perforated ulcer, and sepsis/respiratory failure. One
patient was discharged to the oncological department and
died 12 days after his third surgery in which radical resection
could not be achieved.
Postoperative complications occurred after 6.6% (17/
256) of the procedures and included seven infections, two
pneumonias, two atrial fibrillations, two empyemas, one
pneumothorax, one persistent air leak, one stroke, and one
perforated ulcer.
Twenty-six (10.1%) operations revealed benign histol-
ogy of the resected lesion. Twenty-five (9.8%) operations
revealed a primary lung cancer, and these patients were either
perioperatively treated with lobectomy or entered the formal
TABLE 1. The Surgical Approaches for All Resections,
Surgical Approaches At the First Operation, Surgical
Approach When Staged Surgery, and Number and Type of
Resection for All the Surgeries
No. (%)
Surgical approach total
VATS 60 (23%)
VATS/thoracotomy 53 (21%)
Thoracotomy 143 (56%)
Surgical approach at first operation
VATS 24 (19%)
VATS/thoracotomy 21 (16%)
Thoracotomy 53 (42%)
Staged bilateral surgery 29 (23%)
Surgical approach when staged surgery
Bilateral VATS 3 (10%)
VATS/thoracotomy 6 (21%)
Bilateral thoracotomy 20 (69%)
Type of surgical resection
Wedge 210 (82%)
Segmental 6 (2.5%)
Thoracic wall resection 9 (3.5%)
Lobectomy 21 (8.5%)
Pneumonectomy 2 (0.5%)
Extra pleural pneumonectomy 1 (0.5%)
No resection 7 (2.5%)
VATS, video-assisted thoracoscopic surgery.
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diagnostic protocol for lung cancer. A total of 127 patients
with a total of 205 procedures were therefore included as
having performed radical surgery for pulmonary metastases.
Table 3 is a summary of patient demographics of the patients
with pulmonary metastasectomy.
Exact calculation of DFI was possible in 11 patients. In
most patient charts (N 64), the time of primary surgery was
only noted with month and year of surgery, e.g., March
2002. In these cases, the date of surgery was set to the
15th. In the remaining cases (N  52), only the year of
primary surgery was known, and in this study, the date was
set to the 1st of June.
Ninety-eight patients had unilateral surgery and 29
patients had bilateral metastases and therefore staged bilateral
surgery as their initial surgery. In all, 24 of 127 patients
developed recurrent pulmonary disease. In these patients, 49
repeat resections were performed ranging from one to six
operations.
Completeness of resection was not achieved in eight
(3.1%) patients. Of these, six patients were diagnosed inop-
erable perioperatively, and two patients had microscopically
nonradical surgery and could not tolerate further surgery.
Three patients were lost to follow-up. The mean follow-up
was 61.6  SD 18.1 months.
Colorectal Cancer
Fifty-three patients were resected because of colorectal
metastases, and the median survival was 33.5 months and the
estimated 5-year survival was 50.3% (Figure 1). Of the
prognostic factors analyzed, age, sex, type of resection, type
of surgical approach, the number of metastases, or the pres-
ence of synchronous metastases none significantly influenced
survival. The median DFI between resection of the primary
tumor and lung resection was 13.1 months (range 0–139
months). No cutoff value of DFI was significant. Forty-one
patients presented with unilateral disease and 12 patients
with bilateral disease and thus staged bilateral surgery was
performed. No significant difference in survival was found
(p  0.61).
In seven patients, recurrence of pulmonary metastases
resulted in repeat resections (one to three operations) after the
initial complete resection of lung metastases. Repeat resection
was not associated with an increase in morbidity or mortality or
with a significant difference in survival (p  0.30).
Seven patients had liver resection performed because of
hepatic metastatic disease before lung metastasectomy. For
patients with liver metastases, the median survival and 5-year
TABLE 2. Estimated 5-yr and Median Survival for Each Group of Cancers
Factors Analyzed
Primary Cancer
Colorectal Sarcoma Melanoma Renal Cell Carcinoma Miscellaneous Cancers
No. of patients 53 32 16 10 16
5-yr estimated survival (%) 50.3 21.7 25.0 51.4 50.0
Median survival (mo) 33.5 25.5 10.2 43.4 39.9
Age 60 yr p  0.23 p  0.43 p  0.52 p  0.42 p  0.32
Gender p  0.61 p  0.31 p  0,45 p  0.85 p  0.35
Surgical approach p  0.54 p  0.82 p  0.92 p  0.66 p  0.46
Surgical resection p  0.07 p  0.98 p  0.22 p  0.18 p  0.12
Metastases
1 vs. more p  0.40 p  0.67 p  0.07 p  0.06 p  0.56
2 vs. 3 or more p  0.40 p  0.08 p  0.04 p  0.17 p  0.77
3 vs. 4 or more p  0.11 p  0.11 p  0.12 p  0.39 p  0.39
4 vs. 5 NP p  0.12 NP NP NP
Unilateral vs. staged bilateral surgery p  0.61 p  0.25 p  0.24 p  0.11 p  0.12
DFI
12 mo p  0.76 p  0.09 p  0.41 p  0.04 p  0.03
24 mo p  0.72 p  0.23 p  0.96 p  0.20 p  0.26
36 mo p  0.65 p  0.46 p  0.63 p  0.20 p  0.62
Synchronous metastases p  0.42 p  0.85 p  0.57 p  0.58 NP
Repeat surgery p  0.30 p  0.37 p  0.50 p  0.55 p  0.40
Liver metastases p  0.001 NT NT NT NT
p value for each prognostic factor analyzed is shown.
DFI, disease-free interval; NP, no patients; NT, not tested.
TABLE 3. Patient Demographics
Age, mean (range) yr 57 (16–82)
Sex
Male 61 (48%)
Female 66 (52%)
Primary tumor No. of patients (%)
Colorectal 53 (43)
Sarcoma 32 (24)
Melanoma 16 (13)
Renal cell 10 (7)
Miscellaneous 16 (13)
Journal of Thoracic Oncology • Volume 6, Number 10, October 2011 Outcome after Pulmonary Metastasectomy
Copyright © 2011 by the International Association for the Study of Lung Cancer 1735
estimated survival were 15.4 months and 0% and for patients
without liver metastases 28.6 months and 61.7%, respec-
tively. The difference in survival between these groups was
found to be significant (p  0.001).
In two patients, radical surgery could not be achieved.
They died 18 and 27 months after attempted pulmonary
metastasectomy, respectively.
Sarcoma
Thirty-two patients were resected because of sarcoma
metastases, and the median survival was 25.5 months and the
estimated 5-year survival was 21.7% (Figure 2). The group
was composed of a heterogeneous group of sarcomas such as
osteogenic, Ewing sarcoma, chondrosarcoma, liposarcoma,
synovialsarcoma, and others. Of the prognostic factors ana-
lyzed, age, sex, type of resection, type of surgical approach,
tumor histology, presence of synchronous metastases, or
number of metastases, none significantly influenced survival.
The median DFI between resection of the primary tumor and
lung resection was 21.4 months (range 0–317 months). No
cutoff value of DFI was significant.
Twenty-three patients presented with unilateral dis-
ease and nine patients had bilateral disease and therefore
staged surgery. No statistical difference in survival was
found (p  0.25).
In all, 10 of 32 patients (31%) had repeat surgery for
recurrence of lung metastases after the initial complete resec-
tion of pulmonary metastases. Number of repeat surgery
ranged from one to six operations after initial radical surgery.
Repeat resection was not associated with an increase in
morbidity or mortality or with a significant difference in
survival (p  0.37).
Three patients did not have radical surgery. All were
diagnosed inoperable perioperatively because of extensive
tumor growth. They died after attempted surgery after 4, 5,
and 8 months, respectively.
Melanoma, Renal Cell Carcinoma, and
Miscellaneous Cancers
Sixteen patients were resected because of metastatic
melanoma, and the median survival was 10.2 months and the
estimated 5-year survival was 25.0% (Figure 3). Ten patients
were resected because of renal cell carcinoma metastases, and
the median survival was 43.4 months and the estimated
5-year survival was 51.4% (Figure 4). Sixteen patients had
pulmonary metastasectomy because of miscellaneous pri-
mary tumors (Table 4). For this heterogeneous group, the
median survival was 39.9 months and the estimated 5-year
survival was 50.0%.
Of the prognostic factors analyzed, age, sex, presence
of synchronous metastases, laterality, type of resection, type
of surgical approach, and repeat resection did not signifi-
cantly influence survival.
For malignant melanoma, the number of pulmonary
metastases was found to be a significant prognostic factor.
The cutoff value that significantly differentiated between
good and poor prognosis was found to be two or less metas-
tases with a median and 5-year survival of 17.9 months and
40.0% and 7.3 months and 0% for three or more metastases
(p  0.04). No other differences in number of metastases
FIGURE 1. The estimated 5-year survival after pulmonary
metastasectomy for patients with colorectal metastases.
FIGURE 2. The estimated 5-year survival after pulmonary
metastasectomy for patients with sarcoma metastases.
FIGURE 3. The estimated 5-year survival after pulmonary
metastasectomy for patients with malignant melanoma
metastases.
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were found to be significant. In the renal cell carcinoma or
miscellaneous group, the number of metastases was not
significant.
The DFI was a significant prognostic factor in both the
renal cell carcinoma and the miscellaneous cancers group.
For renal cell carcinoma, the median DFI between resection
of the primary tumor and lung resection was 15 months
(range 0–215 months). A DFI of less than 12 months resulted
in median survival and 5-year estimated survival of 30.6
months and 33.3% in contrast to median survival and 5-year
estimated survival of 55.4 and 75.0% (p  0.04) for a DFI
more than 12 months. For miscellaneous primary tumors, the
median DFI between resection of the primary tumor and lung
resection was 31.3 months (range 11–198 months). A DFI of
less than 12 months resulted in median survival and 5-year
estimated survival of 2.7 months and 0% in contrast to
median survival and 5-year estimated survival of 48.3 and
44.4% (p  0.03) for a DFI 12 months. In both groups,
further statistical analysis of DFI could not demonstrate other
cutoff values of significance. However, one must bear in
mind that the number of patients in these groups is very small
so statistical analysis must be interpreted with caution.
DISCUSSION
During the last decades, pulmonary metastasectomy
has become an increasingly used therapy for various meta-
static malignancies to the lungs with metastasectomy from
colorectal carcinomas and sarcomas being the most common.
However, pulmonary metastases from a wide range of tumors
are being referred for treatment. The search for solid prog-
nostic factors is ongoing and needed. We therefore decided to
retrospectively analyze a recent cohort of 5 years consecutive
pulmonary metastasectomies at our institution to identify
patients who would benefit from surgical resection.
Approximately 10 to 20% of patients with colorectal
cancer will develop pulmonary metastatic disease.3 Isolated
pulmonary metastases without extra-thoracic disease is, how-
ever, rare and accounts for as little as 2% of patients with
metastatic colorectal carcinoma.4 For pulmonary metastases
of colorectal origin, several studies have reported 5-year
survival rates ranging from 27 to 61%.5 In our study, the data
for survival were consistent with these previous studies with
an overall estimated survival of 50.3%. Age and sex were not
significant prognostic factors.
More than half of the patients presented with single
lesions (30/53). Previous studies have demonstrated that the
number of metastases significantly influences survival.6 Usu-
ally, in terms of patients with a single lesion have the best
prognosis or the fewer metastases the better. Phannschmidt
and colleagues reported that patients with up to four metas-
tases demonstrated a better survival than patients with more
than four metastases. Koga et al.7 found the cutoff value to be
3 or less metastases.
In our study, we could not find a cutoff value for the
number of lesions that significantly influenced survival. Nei-
ther could we demonstrate prognostic significance between
patients with unilateral or bilateral disease. However, in our
study, the maximum number of colorectal metastases re-
moved during a single surgery was three metastases, and
most of the patients presented with one or two metastases. A
bias to consider in this study is that perhaps only patients in
good preoperative condition and few metastases (3) are
being referred to surgery, and we therefore only operate on
patients with a good prognosis. Even so, no difference in
survival was found between patients with one or two lesions.
Previous studies have demonstrated the DFI to be a
significant prognostic factor in terms of the longer the DFI,
the better survival.8 The presence of synchronous metastases
as a prognostic factor with an adverse effect on survival has
also been reported.9 In our study, the DFI did not influence
survival, nor did the presence of synchronous metastases.
Approximately 15% of patients resected for colorectal
carcinomas can be expected to have hepatic metastases at the
time of exploration.10 As many as 50% will eventually
develop liver metastases and liver resection, for metastatic
disease is an established treatment. Several studies have
reported no significant adverse effect on survival when per-
forming pulmonary metastasectomy in the presence of pre-
viously complete liver resection.5,8 In our study, we found the
presence of previously treated hepatic metastases to be an
ominous prognostic factor (p  0.001).
FIGURE 4. The estimated 5-year survival after pulmonary
metastasectomy for patients with renal cell carcinoma
metastases.
TABLE 4. Numbers of Different Tumors in the Miscellaneous
Cancers Group
Miscellaneous Cancers
Primary Tumor No. of Cases
Testis 4
Thyroid 4
Parotis 2
Tonsil 1
Uterus 1
Adrenocortical 1
Ovarian 1
Esophagus 1
Bladder 1
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An interesting observation when looking at the Kaplan-
Meier plot is that the survival curve seems to flatten out
indicating that long-term survival is possible.
Patients with sarcoma are particularly prone to develop
pulmonary metastases. In osteosarcoma, 10 to 20% of pa-
tients will have detectable pulmonary lesions at initial diag-
nosis, and up to 70% of patients will develop metachronous
pulmonary metastases.11 Pulmonary metastases in soft tissue
sarcoma are less frequent and develop in approximately 20%
of patients.12
For pulmonary metastases from sarcomas, previous
studies have demonstrated 5-year survival rates between 15
and 37%.13,14 Our survival data with an estimated 5-year
survival of 21.7% were consistent with these previous stud-
ies. Age, sex, surgical approach, type of resection, or the
presence of synchronous metastases did not influence sur-
vival significantly. Previously published significant prognos-
tic factors include number of metastases, laterality, and DFI.
None of these could be confirmed in our study.
Several studies have shown that the complete resection
of pulmonary metastases from sarcomas is a significant prog-
nostic factor.15 In our study, three patients had only explor-
ative surgery because of widespread tumor growth detected
perioperatively. Incomplete resection had a very bad progno-
sis, and all three patients died within 9 months after surgery.
Surgical treatment of lung metastases from melanoma
is controversial as the expected outcome is much poorer than
for other primary tumors. Malignant melanomas’ ability to
widespread dissemination causes the number of patients eli-
gible for pulmonary metastasectomy to be very small as
patients with isolated pulmonary metastases are a very small
proportion of patients with disseminated malignant mela-
noma. Once malignant melanoma has spread to a distant site,
the median survival is 8 months and 5-year survival is less
than 5%.16 Previous studies with pulmonary metastasectomy
from malignant melanoma have demonstrated 5-year survival
rates of up to 33%17 and thus far superior to medical treat-
ment alone. Our survival data with an estimated 5-year
survival of 25.0% were consistent with these previous stud-
ies. The presence of single metastasis and complete resection
are the most often published significant prognostic factors.
We also found the number metastases to be significant. Two
metastases or fewer were significantly associated with pro-
longed survival. In the International Registry of Lung Metas-
tases,6 a DFI of more than 36 months was also found to be
significant but this could not be confirmed in our study. None
of the other analyzed factors in our study were significant.
However, the number of patients in the melanoma group in
our study is small (N  16) so the statistical analysis must be
interpreted cautiously.
Approximately 25 to 30% of patients with renal cell
carcinoma will have metastatic disease at diagnosis and a
further 30% of patients will eventually develop metastases
with the lungs being the most common organ.18 Previous
studies have demonstrated 5-year survival rates of up to 40%
after pulmonary metastasectomy from renal cell carcinoma.19
Our results are consistent with these findings. Previously
investigated significant prognostic factors that influence sur-
vival include complete resection, number of metastases, DFI,
and lymph node status.19 In our analysis, only a DFI less than
12 months was confirmed as a significant prognostic factor
with adverse effect on survival. However, because of the
small number of patients (N  10), the statistical analysis
must be interpreted cautiously.
The subgroup with miscellaneous primary tumors
represents such a heterogeneous group of cancers (Table 4)
from which no conclusion can be drawn from this group.
However, emphasis must be put on that every patient is
examined carefully for the eligibility for potential pulmo-
nary metastasectomy.
The surgical approach in pulmonary metastasectomy
remains a controversial issue. Open surgery through lateral
thoracotomy, median sternotomy, or even clamshell incision
enables the surgeon to perform bimanual palpation of the
whole lung and thereby potentially detect lesions missed by
preoperative imaging. Several studies have shown the inad-
equacy of preoperative CT scan, even with high-resolution
helical scanners, to detect all pulmonary lesions found during
surgery.20
VATS is a less invasive procedure resulting in less
surgical trauma and postoperative morbidity.21 In the case of
repeat surgery for recurrence of pulmonary disease, it does
not complicate a potential reoperation by thoracotomy. The
disadvantage is the lack of tactile sensation and the risk of
missing lesions that could possibly have been detected with
conventional thoracotomy and bimanual palpation.
However, with the improvement in radiology and sur-
gical techniques, several more recent studies have now been
published investigating the VATS approach in pulmonary
metastasectomy and demonstrating survival rates equivalent
to open surgery.22,23 These studies only investigated patients
with small (3 cm) and few (2) metastases.
At our institution, the current approach is to perform
thoracoscopy in patients with few lesions (2) located in the
periphery of the lung. In the case of inability to achieve
certain R0 resection, the procedure is converted to open
surgery. The remaining patients will have conventional open
surgery performed.
In our study, no significant difference in survival was
observed between patients who had thoracoscopy or thora-
cotomy performed, regardless of primary tumor (colorectal,
p  0.54; sarcoma, p  0.82; melanoma, p  0.92; or renal
cell carcinoma, p  0.66). Hence, our current practice seems
justified.
Twenty-four (18.9%) patients developed recurrence of
pulmonary metastases and 49 repeat surgeries were per-
formed ranging from one to six operations in a single patient.
Sarcoma patients (10/32) were the most likely to develop
recurrence followed by renal cell carcinoma (2/10) and colo-
rectal (7/53) patients. All but one patient developed recur-
rence in a different lobe from where the previous resection
was performed. The one patient with six repeat resections had
osteosarcoma as the primary malignancy, and in two of these
resections, recurrence of disease developed in a lobe where a
previous resection had been performed.
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The estimated 5-year survival of patients who under-
went repeated surgery for recurrent pulmonary metastases did
not differ significantly from those who only had single/staged
surgery (colorectal p  0.30; sarcoma, p  0.37; melanoma,
p  0.50; or renal cell carcinoma, p  0.55). This indicates
that as long as a patient can fulfill the initial criteria for
pulmonary metastasectomy, repeat surgery is not an omi-
nous prognostic factor and surgery should be attempted.
Aggressive follow-up after pulmonary metastasectomy
must be conducted.
Initially, 32 patients had thoracoscopy performed, 24
had thoracoscopy converted to thoracotomy performed, and
71 had thoracotomy performed. In the thoracoscopy, group 6
patients developed recurrence (18.7%), and in the combined
group of thoracoscopy converted to thoracotomy and only
thoracotomy, 18 patients developed recurrence (18.9%).
Hence, no difference in recurrence between the two groups
could be demonstrated.
Regarding survival, when the six patients with tho-
racoscopy were analyzed against the other patients with
recurrence where thoracotomy was performed, no significant
difference in survival could be demonstrated (p  0.34).
In addition, the thoracoscopic approach seems justified
in appropriately selected patients. The question of lymph
node sampling and/or involvement remains controversial.
The performance of lymph node dissection during pulmonary
metastasectomy is infrequent and varies between institutions,
including our own. Of all the patients in The International
Registry of Lung Metastases, only 4.6% of patients under-
went lymph node dissection. In a recent survey by Internullo
et al., among the members of European Society of Thoracic
Surgeons, 55% perform mediastinal lymph node sampling,
whereas 33% perform no nodal sampling at all. The rate of
lymph node involvement varies between primary tumors.
Phannschmidt and colleagues performed systemic lymph
node dissection in concurrence with pulmonary metastasec-
tomy in 245 patients with metastases from colorectal carci-
noma, renal cell carcinoma, and sarcoma. Nodal involvement
was more frequent in renal cell carcinoma (42.4%) and
colorectal carcinoma (31.3%) than sarcomas (20.3%). Sev-
eral studies have found the presence of positive intrathoracic
lymph nodes, an ominous prognostic factor. Ercan and col-
leagues found a 3-year survival of 69% for patients without
lymph node involvement versus 38% in patients with positive
lymph nodes. Saito and colleagues reported a 5-year survival
of 53.6 for patients without hilar or mediastinal node involve-
ment versus 6.2% at 4 years for patients with positive nodes.
It remains unclear whether the removal of these lymph
nodes confers a survival benefit or merely allow for a more
accurate postoperative staging and guidance for additional
oncological treatment. The above-mentioned authors pro-
posed the latter.
CONCLUSION
Patients with untreated metastatic disease have a 5-year
survival rate of less than 5 to 10%, and for a patient with
isolated metastatic disease of the lungs, pulmonary metasta-
sectomy is often the best hope for cure. It is a safe and
effective treatment that leads to possible cure in selected
patients. Regardless of primary tumor, completeness of re-
section is the key to improved survival. Low morbidity and
mortality rates in contrast with the lack of any other effective
systemic oncological treatment justify the aggressive ap-
proach of surgery. Thoracoscopic resection is a valid option
in selected patients with few, peripherally located metastases.
In case of recurrence of pulmonary disease and if the patient
fulfils the initial criteria for pulmonary metastasectomy, re-
peat surgery should be performed. Aggressive postoperative
follow-up is warranted. The patients should be treated in
close collaboration between the medical oncologist, diagnos-
tic radiologist, and thoracic surgeon.
However, despite numerous studies and decades of
metastasectomies, the lack of randomized studies continues
to make the effect of pulmonary metastasectomy question-
able. Most studies have been retrospective and the biases are
many: possibly only patients in good physical condition are
referred, possibly only patients with slow-growing tumors
are referred (time-length bias), or possibly earlier detection
through more aggressive follow-up leads to earlier surgery
with a seemingly longer survival. Most reports recommend
pulmonary metastasectomy for a properly selected group of
patients. However, the case-mix from which patients are
selected for surgery is rarely described.
Whether the survival of these patients is based on
selection rather than surgery is still not clear. As argued by
Treasure,24 among others it remains “a common practice
based on weak evidence.”
Furthermore, prognostic factors that determine which
patients benefit from surgery are still not clearly established.
To determine how to select surgical candidates for pulmonary
metastasectomy, more precisely further analysis of prognos-
tic factors is evident, and the need for a prospective, random-
ized, multicenter study is clear. The recently opened Pul-
MiCC trial25 may provide some answers.
REFERENCES
1. Davidson RS, Nwogu CE, Brentjens MJ, et al. The surgical management
of pulmonary metastasis: current concepts. Surg Oncol 2001;10:35–42.
2. Internullo E, Cassivi SD, Van RD, et al. Pulmonary metastasectomy: a
survey of current practice amongst members of the European Society of
Thoracic Surgeons. J Thorac Oncol 2008;3:1257–1266.
3. August DA, Ottow RT, Sugarbaker PH. Clinical perspective of human
colorectal cancer metastasis. Cancer Metastasis Rev 1984;3:303–324.
4. McCormack PM, Burt ME, Bains MS, et al. Lung resection for colo-
rectal metastases. 10-year results. Arch Surg 1992;127:1403–1406.
5. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of
pulmonary metastases from colorectal cancer: a systematic review of
published series. Ann Thorac Surg 2007;84:324–338.
6. Long-term results of lung metastasectomy: prognostic analyses based on
5206 cases. The International Registry of Lung Metastases. J Thorac
Cardiovasc Surg 1997;113:37–49.
7. Koga R, Yamamoto J, Saiura A, et al. Surgical resection of pulmonary
metastases from colorectal cancer: four favourable prognostic factors.
Jpn J Clin Oncol 2006;36:643–648.
8. Ike H, Shimada H, Togo S, et al. Sequential resection of lung metastasis
following partial hepatectomy for colorectal cancer. Br J Surg 2002;89:
1164–1168.
9. Rama N, Monteiro A, Bernardo JE, et al. Lung metastases from colo-
rectal cancer: surgical resection and prognostic factors. Eur J Cardio-
thorac Surg 2009;35:444–449.
Journal of Thoracic Oncology • Volume 6, Number 10, October 2011 Outcome after Pulmonary Metastasectomy
Copyright © 2011 by the International Association for the Study of Lung Cancer 1739
10. Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management
of liver metastases from colorectal cancer. Ann Surg 2006;244:254–259.
11. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with
clinically detectable metastasis at initial presentation. J Clin Oncol
1993;11:449–453.
12. van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung
metastases: The European Organization for Research and Treatment of
Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients.
Cancer 1996;77:675–682.
13. Smith R, Pak Y, Kraybill W, et al. Factors associated with actual
long-term survival following soft tissue sarcoma pulmonary metastasec-
tomy. Eur J Surg Oncol 2009;35:356–361.
14. Pfannschmidt J, Klode J, Muley T, et al. Pulmonary metastasectomy in
patients with soft tissue sarcomas: experiences in 50 patients. Thorac
Cardiovasc Surg 2006;54:489–492.
15. Kempf-Bielack B, Bielack SS, Ju¨rgens H, et al. Osteosarcoma relapse
after combined modality therapy: an analysis of unselected patients in
the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol
2005;23:559–568.
16. Lee ML, Tomsu K, Von Eschen KB. Duration of survival for dissemi-
nated malignant melanoma: results of a meta-analysis. Melanoma Res
2000;10:81–92.
17. Andrews S, Robinson L, Cantor A, et al. Survival after surgical resection
of isolated pulmonary metastases from malignant melanoma. Cancer
Control 2006;13:218–223.
18. Hofmann HS, Neef H, Krohe K, et al. Prognostic factors and survival
after pulmonary resection of metastatic renal cell carcinoma. Eur Urol
2005;48:77–81.
19. Piltz S, Meimarakis G, Wichmann MW, et al. Long-term results after
pulmonary resection of renal cell carcinoma metastases. Ann Thorac
Surg 2002;73:1082–1087.
20. Ludwig C, Cerinza J, Passlick B, et al. Comparison of the number of
pre-, intra- and postoperative lung metastases. Eur J Cardiothorac Surg
2008;33:470–472.
21. Landreneau RJ, Wiechmann RJ, Hazelrigg SR, et al. Effect of minimally
invasive thoracic surgical approaches on acute and chronic postoperative
pain. Chest Surg Clin N Am 1998;8:891–906.
22. Mutsaerts EL, Zoetmulder FA, Meijer S, et al. Long term survival of
thoracoscopic metastasectomy vs metastasectomy by thoracotomy in
patients with a solitary pulmonary lesion. Eur J Surg Oncol 2002;28:
864–868.
23. Gossot D, Radu C, Girard P, et al. Resection of pulmonary metastases
from sarcoma: can some patients benefit from a less invasive approach?
Ann Thorac Surg 2009;87:238–243.
24. Treasure T. Pulmonary metastasectomy: a common practice based on
weak evidence. Ann R Coll Surg Engl 2007;89:744–748.
25. Treasure T, Fallowfield L, Lees B. Pulmonary metastasectomy in
colorectal cancer: the PulMiCC trial. J Thorac Oncol 2010;5:S203–
S206.
Hornbech et al. Journal of Thoracic Oncology • Volume 6, Number 10, October 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1740
